Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".
Panza F, Saladini F, Bartolini N, Gianmarino F, Montagnani F, Spagnuolo V, Tumbarello M, Santoro MM, Castagna A, Zazzi M, Fabbiani M. Panza F, et al. Among authors: montagnani f. New Microbiol. 2024 May;47(1):116-122. New Microbiol. 2024. PMID: 38700893 Free article.
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Gagliardini R, Baccini M, Modica S, Montagnani F, Zanelli G, Borghetti A, Dreassi E, Lombardi F, Pecorari M, Borghi V, Callegaro A, Micheli V, Lodi MA, Rossetti B, Zazzi M; ARCA cohort. Gagliardini R, et al. Among authors: montagnani f. J Glob Antimicrob Resist. 2022 Mar;28:274-281. doi: 10.1016/j.jgar.2022.01.018. Epub 2022 Jan 26. J Glob Antimicrob Resist. 2022. PMID: 35092828 Free article.
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Fabbiani M, Masini M, Rossetti B, Ciccullo A, Borghi V, Lagi F, Capetti A, Colafigli M, Panza F, Baldin G, Mussini C, Sterrantino G, Farinacci D, Montagnani F, Tumbarello M, Di Giambenedetto S. Fabbiani M, et al. Among authors: montagnani f. Viruses. 2023 May 8;15(5):1123. doi: 10.3390/v15051123. Viruses. 2023. PMID: 37243208 Free PMC article.
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M, Borghetti A, Squillace N, Colafigli M, Taramasso L, Lombardi A, Rossetti B, Ciccullo A, Colella E, Picarelli C, Berruti M, Latini A, Montagnani F, Sambo M, Di Biagio A, Gori A, Di Giambenedetto S, Bandera A. Fabbiani M, et al. Among authors: montagnani f. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):119-127. doi: 10.1097/QAI.0000000000002525. J Acquir Immune Defic Syndr. 2021. PMID: 33306566
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S; ODOACRE Study Group. Fabbiani M, et al. Among authors: montagnani f. HIV Med. 2021 Oct;22(9):843-853. doi: 10.1111/hiv.13146. Epub 2021 Jul 27. HIV Med. 2021. PMID: 34318591 Free article.
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV.
Polvere J, Fabbiani M, Pastore G, Rancan I, Rossetti B, Durante M, Zirpoli S, Morelli E, Pettini E, Lucchesi S, Fiorino F, Tumbarello M, Ciabattini A, Montagnani F, Medaglini D. Polvere J, et al. Among authors: montagnani f. Commun Med (Lond). 2023 Jan 30;3(1):13. doi: 10.1038/s43856-023-00245-5. Commun Med (Lond). 2023. PMID: 36717688 Free PMC article.
140 results